智通财经APP讯,中国中药(00570)发布截至2025年12月31日止年度业绩,集团营业额人民币147.45亿元,同比减少10.7%;净亏损4.58亿元,同比盈转亏;每股基本亏损6.79分。
公告称,期间亏损主要由于中药配方颗粒业务受集采业务占比提高、市场竞争加剧等影响,收入规模及盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加。
智通财经APP讯,中国中药(00570)发布截至2025年12月31日止年度业绩,集团营业额人民币147.45亿元,同比减少10.7%;净亏损4.58亿元,同比盈转亏;每股基本亏损6.79分。
公告称,期间亏损主要由于中药配方颗粒业务受集采业务占比提高、市场竞争加剧等影响,收入规模及盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.